1 week Ago By Defense World Staff
JPMorgan Chase & Co. grew its holdings in Catalyst Pharmaceuticals, Inc. ( NASDAQ:CPRX – Free Report ) by 80.
3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 736,197 shares of the biopharmaceutical company’s stock after acquiring an additional 327,936 shares during the quarter. JPMorgan Chase & Co.
owned 0.62% of Catalyst Pharmaceuticals worth $15,364,000 as of its most recent SEC filing. Several other institutional investors and hedge funds have also modified their holdings of CPRX.
Vanguard Group Inc. boosted its holdings in Catalyst Pharmaceuticals by 4.9% in the 4th quarter.
Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company’s stock valued at $175,957,000 after purchasing an additional 390,116 shares during the period. Pacer Advisors Inc.
raised its position in shares of Catalyst Pharmaceuticals by 5.4% in the fourth quarter. Pacer Advisors Inc.
now owns 2,955,508 shares of the biopharmaceutical company’s stock valued at $61,681,000 after buying an additional 151,495 shares in the last quarter. Boston Partners boosted its stake in shares of Catalyst Pharmaceuticals by 1.3% in the fourth quarter.
Boston Partners now owns 1,291,868 shares of the biopharmaceutical company’s stock valued at $27,325,000 after buying an additional 16,601 shares during the period. Charles Schwab Investment Management Inc. grew its position in Catalyst Pharmaceuticals by 6.
8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,246,925 shares of the biopharmaceutical company’s stock worth $26,023,000 after buying an additional 79,182 shares in the last quarter.
Finally, Skandinaviska Enskilda Banken AB publ grew its position in Catalyst Pharmaceuticals by 74.3% during the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 731,900 shares of the biopharmaceutical company’s stock worth $15,421,000 after buying an additional 312,000 shares in the last quarter.
79.22% of the stock is currently owned by institutional investors and hedge funds. Wall Street Analyst Weigh In A number of research firms have recently weighed in on CPRX.
Stephens reiterated an “overweight” rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. StockNews.
com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th.
Bank of America reaffirmed a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Finally, Robert W.
Baird increased their price target on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, March 3rd.
Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $32.29.
Catalyst Pharmaceuticals Trading Up 2.8 % CPRX opened at $22.05 on Friday.
The company has a market cap of $2.68 billion, a P/E ratio of 18.69, a PEG ratio of 3.
31 and a beta of 0.79. The company’s 50 day moving average is $22.
63 and its 200-day moving average is $22.00. Catalyst Pharmaceuticals, Inc.
has a 1-year low of $14.47 and a 1-year high of $26.16.
Insider Activity at Catalyst Pharmaceuticals In other news, insider Gary Ingenito sold 44,904 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.
36. Following the completion of the transaction, the insider now directly owns 68,873 shares in the company, valued at approximately $1,521,404.57.
This represents a 39.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website .
Also, insider Brian Elsbernd sold 62,975 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.
50. Following the sale, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72.
This trade represents a 25.04 % decrease in their position. The disclosure for this sale can be found here .
11.00% of the stock is owned by insiders. Catalyst Pharmaceuticals Profile ( Free Report ) Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.
It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. Featured Articles Five stocks we like better than Catalyst Pharmaceuticals Using the MarketBeat Dividend Tax Calculator Robinhood Strategies Could Be a Game-Changer for Young Investors Stock Analyst Ratings and Canadian Analyst Ratings Are These 3 Retail Stocks Oversold or Really in Trouble? Top Stocks Investing in 5G Technology IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
